CTLA-4·FasL induces early apoptosis of activated T cells by interfering with anti-apoptotic signals

Journal of Immunology

Volumn 179, Issue 11, 2007, Pages 7287-7294

  Orbach, Ariel ^a   Rachmilewitz, Jacob ^a   Parnas, Miram ^a   Huang, Jui Han ^b   Tykocinski, Mark L ^b   Dranitzki Elhalel, Michael ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CASPASE 3; CASPASE 8; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 FAS LIGAND FUSION PROTEIN; DEATH RECEPTOR; FLICE INHIBITORY PROTEIN; HYBRID PROTEIN; LIPOCORTIN 5; PROPIDIUM IODIDE; TRANS SIGNAL CONVERTER PROTEIN; UNCLASSIFIED DRUG; BENZYLOXYCARBONYLVALYL ALANYL ASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; FAS LIGAND; LEUKOCYTE ANTIGEN; PEPTIDE CHLOROMETHYL KETONE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; FLOW CYTOMETRY; IMMUNOPHARMACOLOGY; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; UPREGULATION;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; FAS LIGAND PROTEIN; FEMALE; MICE; MICE, INBRED C57BL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; UP-REGULATION;

EID: 38849092640     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.11.7287     Document Type: Article

References (51)

1. Kreitman, R. J., W. H. Wilson, K. Bergeron, M. Raggio, M. Stetler-Stevenson, D. J. FitzGerald, and I. Pastan. 2001. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345: 241-247.
2. Foss, F. M., P. Bacha, K. E. Osann, M. F. Demierre, T. Bell, and T. Kuzel. 2001. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin. Lymphoma 1: 298-302.
3. Kreitman, R. J. 2006. Immunotoxins for targeted cancer therapy. Aaps J. 8: E532-E551.
4. Casares, S., C. S. Zong, D. L. Radu, A. Miller, C. A. Bona, and T. D. Brumeanu. 1999. Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation. J. Exp. Med. 190: 543-553.
5. Schmoekel, H. G., F. E. Weber, J. C. Schense, K. W. Gratz, P. Schawalder, and J. A. Hubbell. 2005. Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnol. Bioeng. 89: 253-262.
6. Bulfone-Paus, S., R. Ruckert, H. Krause, H. von Bernuth, M. Notter, T. Pohl, T. H. Tran, R. Paus, and U. Kunzendorf. 2000. An interleukin-2-IgG-Fas ligand fusion protein suppresses delayed-type hypersensitivity in mice by triggering apoptosis in activated T cells as a novel strategy for immunosuppression. Transplantation 69: 1386-1391.
7. Huang, J. H., and M. L. Tykocinski. 2001. CTLA-4-Fas ligand functions as a trans signal converter protein in bridging antigen-presenting cells and T cells. Int. Immunol. 13: 529-539.
8. Dranitzki Elhalel, M., J.-H. Huang, M. Sasoon, J. Rachmilewitz, M. Parnas, and M. L. Tykocinski. 2005. CD40·FasL inhibits human T cells: evidence for an auto-inhibitory loop-back mechanism. Am. J. Soc. Nephrol. 16: 232A.
9. Assohou-Luty, C., J. Gerspach, D. Siegmund, N. Muller, B. Huard, G. Tiegs, K. Pfizenmaier, and H. Wajant. 2006. A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. J. Mol. Med. 84: 785-797.
10. Gerspach, J., D. Muller, S. Munkel, O. Selchow, J. Nemeth, M. Noack, H. Petrul, A. Menrad, H. Wajant, and K. Pfizenmaier. 2006. Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase- mediated processing of a TNF prodrug. Cell Death Differ. 13: 273-284.
11. Samel, D., D. Muller, J. Gerspach, C. Assohou-Luty, G. Sass, G. Tiegs, K. Pfizenmaier, and H. Wajant. 2003. Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted Activation. J. Biol. Chem. 278: 32077-32082.
12. Dranitzki-Elhalel, M., J. Huang, M. Sasson, J. Rachmilewitz, M. Parnas, and M. Tykocinski. 2007. CD40·FasL inhibits human T cells: evidence for an autoinhibitory loop-back mechanism. Int. Immunol. 19: 355-363.
13. Elhalel, M. D., J. H. Huang, W. Schmidt, J. Rachmilewitz, and M. L. Tykocinski. 2003. CTLA-4. FasL induces alloantigen-specific hyporesponsiveness. J. Immunol. 170: 5842-5850.
14. Dranitzki-Elhalel, M., J. H. Huang, J. Rachmilewitz, O. Pappo, M. Parnas, W. Schmidt, and M. L. Tykocinski. 2006. CTLA-4.FasL inhibits allogeneic responses in vivo. Cell. Immunol. 239: 129-135.
15. Chen, L. 2004. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4: 336-347.
16. Nagata, S. 1999. Fas ligand-induced apoptosis. Annu. Rev. Genet. 33: 29-55.
17. Keller, S. A., D. Hernandez-Hopkins, J. Vider, V. Ponomarev, E. Hyjek, E. J. Schattner, and E. Cesarman. 2006. NF-κB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood 107: 3295-3302.
18. Zhang, H. G., X. Su, D. Liu, W. Liu, P. Yang, Z. Wang, C. K. Edwards, H. Bluethmann, J. D. Mountz, and T. Zhou. 1999. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. J. Immunol. 162: 1423-1430.
19. Feng, Y. G., Y. Z. Jin, Q. Y. Zhang, J. Hao, G. M. Wang, and S. S. Xie. 2005. CTLA4-Fas ligand gene transfer mediated by adenovirus induce long-time survival of murine cardiac allografts. Transplant. Proc. 37: 2379-2381.
20. Jin, Y., A. Qu, G. M. Wang, J. Hao, X. Gao, and S. Xie. 2004. Simultaneous stimulation of Fas-mediated apoptosis and blockade of costimulation prevent autoimmune diabetes in mice induced by multiple low-dose streptozotocin. Gene Ther. 11: 982-991.
21. Vincenti, F., C. Larsen, A. Durrbach, T. Wekerle, B. Nashan, G. Blancho, P. Lang, J. Grinyo, P. F. Halloran, K. Solez, D. Hagerty, et al. 2005. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 353: 770-781.
22. Bluestone, J. A., E. W. St Clair, and L. A. Turka. 2006. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24: 233-238.
23. Janeway, C. A., Jr., and K. Bottomly. 1994. Signals and signs for lymphocyte responses. Cell 76: 275-285.
24. Greenwald, R. J., V. A. Boussiotis, R. B. Lorsbach, A. K. Abbas, and A. H. Sharpe. 2001. CTLA-4 regulates induction of anergy in vivo. Immunity 14: 145-155.
25. Greenwald, R. J., M. A. Oosterwegel, D. van der Woude, A. Kubal, D. A. Mandelbrot, V. A. Boussiotis, and A. H. Sharpe. 2002. CTLA-4 regulates cell cycle progression during a primary immune response. Eur. J. Immunol. 32: 366-373.
26. Wekerle, T., J. Kurtz, M. Sayegh, H. Ito, A. Wells, S. Bensinger, J. Shaffer, L. Turka, and M. Sykes. 2001. Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J. Immunol. 166: 2311-2316.
27. + T cell apoptosis but not immune deviation. Transplantation 69: 1176-1185.
28. + T lymphocyte by adenovirus-mediated gene transfer of CTLA4Ig fusion protein in experimental autoimmune myocarditis. Autoimmunity 39: 289-298.
29. Grohmann, U., F. Fallarino, and P. Puccetti. 2003. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24: 242-248.
30. Grohmann, U., C. Orabona, F. Fallarino, C. Vacca, F. Calcinaro, A. Falorni, P. Candeloro, M. L. Belladonna, R. Bianchi, M. C. Fioretti, and P. Puccetti. 2002. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3: 1097-1101.
31. Alderson, M. R., R. J. Armitage, E. Maraskovsky, T. W. Tough, E. Roux, K. Schooley, F. Ramsdell, and D. H. Lynch. 1993. Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med. 178: 2231-2235.
32. Kennedy, N. J., T. Kataoka, J. Tschopp, and R. C. Budd. 1999. Caspase activation is required for T cell proliferation. J. Exp. Med. 190: 1891-1896.
33. Maksimow, M., T. S. Soderstrom, S. Jalkanen, J. E. Eriksson, and A. Hanninen. 2006. Fas costimulation of naive CD4 T cells is controlled by NF-κB signaling and caspase activity. J. Leukocyte Biol. 79: 369-377.
34. Klas, C., K. M. Debatin, R. R. Jonker, and P. H. Krammer. 1993. Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol. 5: 625-630.
35. O'Flaherty, E., S. Ali, S. J. Pettit, and J. A. Kirby. 1998. Examination of the sensitivity of T cells to Fas ligation: induction of allospecific apoptosis. Transplantation 66: 1067-1073.
36. O'Flaherty, E., W. K. Wong, S. J. Pettit, K. Seymour, S. Ali, and J. A. Kirby. 2000. Regulation of T-cell apoptosis: a mixed lymphocyte reaction model. Immunology 100: 289-299.
37. Kirchhoff, S., W. W. Muller, A. Krueger, I. Schmitz, and P. H. Krammer. 2000. TCR-mediated up-regulation of c-FLIPshort correlates with resistance toward CD95-mediated apoptosis by blocking death-inducing signaling complex activity. J. Immunol. 165: 6293-6300.
38. Lee, S. W., Y. Park, J. K. Yoo, S. Y. Choi, and Y. C. Sung. 2003. Inhibition of TCR-induced CD8 T cell death by IL-12: regulation of Fas ligand and cellular FLIP expression and caspase activation by IL-12. J. Immunol. 170: 2456-2460.
39. Wells, A. D., X. C. Li, Y. Li, M. C. Walsh, X. X. Zheng, Z. Wu, G. Nunez, A. Tang, M. Sayegh, W. W. Hancock, et al. 1999. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5: 1303-1307.
40. Wells, A. D., X. C. Li, T. B. Strom, and L. A. Turka. 2001. The role of peripheral T-cell deletion in transplantation tolerance. Philos. Trans. R Soc. Lond B Biol. Sci. 356: 617-623.
41. Kirchhoff, S., W. W. Muller, M. Li-Weber, and P. H. Krammer. 2000. Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28-costimulated human T cells. Eur. J. Immunol. 30: 2765-2774.
42. Scaffidi, C., I. Schmitz, P. H. Krammer, and M. E. Peter. 1999. The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 274: 1541-1548.
43. Thome, M., P. Schneider, K. Hofmann, H. Fickenscher, E. Meinl, F. Neipel, C. Mattmann, K. Burns, J. L. Bodmer, M. Schroter, et al. 1997. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386: 517-521.
44. Maksimow, M., M. Santanen, S. Jalkanen, and A. Hanninen. 2003. Responding naive T cells differ in their sensitivity to Fas engagement: early death of many T cells is compensated by costimulation of surviving T cells. Blood 101: 4022-4028.
45. Chau, H., V. Wong, N. J. Chen, H. L. Huang, W. J. Lin, C. Mirtsos, A. R. Elford, M. Bonnard, A. Wakeham, A. I. You-Ten, et al. 2005. Cellular FLICE-inhibitory protein is required for T cell survival and cycling. J. Exp. Med. 202: 405-413.
46. Kataoka, T., R. C. Budd, N. Holler, M. Thome, F. Martinon, M. Irmler, K. Burns, M. Hahne, N. Kennedy, M. Kovacsovics, and J. Tschopp. 2000. The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Curr. Biol. 10: 640-648.
47. Mellor, A. L., B. Baban, P. Chandler, B. Marshall, K. Jhaver, A. Hansen, P. A. Koni, M. Iwashima, and D. H. Munn. 2003. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 171: 1652-1655.
48. Mellor, A. L., P. Chandler, B. Baban, A. M. Hansen, B. Marshall, J. Pihkala, H. Waldmann, S. Cobbold, E. Adams, and D. H. Munn. 2004. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int. Immunol. 16: 1391-1401.
49. Baban, B., A. M. Hansen, P. R. Chandler, A. Manlapat, A. Bingaman, D. J. Kahler, D. H. Munn, and A. L. Mellor. 2005. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int. Immunol. 17: 909-919.
50. Schneider, P., N. Holler, J. L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187: 1205-1213.
51. Knox, P. G., A. E. Milner, N. K. Green, A. G. Eliopoulos, and L. S. Young. 2003. Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand. J. Immunol. 170: 677-685.